The most important feature determining survival in carcinoma of the cervix is thought to be the clinical stage of the tumour at presentation (Kottmeier, 1971) . Other clinical parameters of importance include the size of the primary tumour (Montana et. al., 1983) and involvement of the pelvic lymph nodes at Wertheim's hysterectomy (Alcock & Toplis, 1987) . It has also been suggested that younger patients have a poorer prognosis (Hall & Monaghan, 1983) , although this has been disputed (Russell et al., 1987) . Despite these parameters, cases with an apparently good prognosis often do badly and vice versa (Wiernik, 1986) .
The value of histological and immunological features in predicting the clinical course remains controversial. Studies of cell size, tumour differentiation or presence of antigenic markers each have their advocates (Ng & Atkin, 1973; van Nagell et al., 1977; Bobrow et al., 1986) and opponents (Crissman et al., 1985; Goellner, 1976; Wells et al., 1986; Fray et al., 1984) .
The measurement of tumour growth fraction offers a potentially valuable approach to predicting clinical behaviour and may also assist in optimising radiation dose schedules (Wilson et al., 1988a) .
Monoclonal antibody, Ki-67, identifies a nuclear associated antigen in human cells which is present in all stages of the cell cycle except Go (Gerdes et al., 1984a; Brown & Gatter, 1990; Gerdes et al., 1991) . A good correlation has been shown between the immunocytochemical labelling of cell nuclei with Ki-67 and other methods of assessing cell proliferation, e.g. flow cytometry and autoradiography (Gerdes et al., 1984a) . Preliminary studies of lymphoma (Gerdes et al., 1984b; Hall et al., 1988) , breast cancer and carcinoma of the lung (Gatter et al., 1986) have shown that Ki-67 gives a rapid and reliable estimate of the tumour growth fraction.
In a previous study it was shown (Brown et al., 1988 ) that there was little correlation between conventional histological classification of carcinoma of the cervix and the growth fraction as measured by Ki-67. This suggested that Ki-67 immunostaining might provide an independent means of assessing clinical behaviour in cervical neoplasia. The present study was therefore undertaken to determine the value of estimating tumour growth fraction immunocytochemically in a number of patients with carcinoma of the cervix followed clinically for periods between 3-5 years.
The pathological material for this study was Immunocytochemistry was performed using the alkaline phosphatase: anti-alkaline phosphatase (APAAP) technique (Cordell et al., 1984) . The assessment of tumour cell proliferation using the monoclonal antibody Ki-67 and the assignation of tumour grade and type have been described previously (Brown et al., 1988) .
The clinical information collected included age, FIGO (International Federation of Obstetrics and Gynaecology) stage, nodal status at Wertheim's hysterectomy and survival. Surgical confirmation of nodal status in the majority of patients was possible because of the policy of combined modality treatment using pre-operative intracavitary irradiation followed by Wertheim's hysterectomy.
Statistical analysis was performed using Student's t-test and Fisher's exact probability test (Swinscow, 1983) . Calculation of survival curves was achieved using Microsoft Excel (version 2.2) software.
The clinical and pathological information for the 28 patients investigated in this study is summarised in Table I. The probabilities of a relationship existing between the parameters recorded in this study are shown in Table II Figure 1 Survival curves of patients with cervical carcinoma of low and high proliferative grades ( < 30% and > 30%) as assessed by antibody . AD-Low Ki-67, -*-High Clinical evaluation and diagnostic imaging often fail to indicate the local extent of tumour in carcinoma of the cervix (Alcock & Toplis, 1987) . Because staging is less than 100% reliable, some patients receive more, and others less, treatment than is necessary. The curability of stage I carcinoma of the cervix is 75% (Wiernik, 1986) (Brown et al., 1988 show Ki-67 as an independent discriminator between low and high risk groups may be, in part, due to the relatively small number of patients in this study (necessitated by the need to recruit patients prospectively for fresh biopsy samples). A larger study might reveal an influence on prognosis that went undetected in the current investigation.
The inability of Ki-67 to act as a prognostic indicator in cervical carcinoma is in keeping with the findings of Tungekar et al. (1991) who studied 187 lung tumours and found that Ki-67 did not provide any additional prognostic information to that already obtained from histological assessment. Indeed both of these studies (lung tumours and cervical carcinoma) are in keeping with the general impression given in the review of this antibody (Brown & Gatter, 1990 ) that the role of Ki-67 in predicting a tumour's clinical behaviour is most convincingly demonstrated in lymphoproliferative disorders and connective tissue diseases rather than carcinomas.
